Nicotinamide and NAFLD: Is There Nothing New Under the Sun?
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Nicotinamide adenine dinucleotide (NAD) has a critical role in cellular metabolism and energy homeostasis. Its importance has been established early with the discovery of NAD’s therapeutic role for pellagra. This review addresses some of the recent findings on NAD physiopathology and their effects on nonalcoholic fatty liver disease (NAFLD) pathogenesis, which need to be considered in the search for a better therapeutic approach. Reduced NAD concentrations contribute to the dysmetabolic imbalance and consequently to the pathogenesis of NAFLD. In this perspective, the dietary supplementation or the pharmacological modulation of NAD levels appear to be an attractive strategy. These reviewed studies open the doors to growing interest in NAD metabolism for NAFLD diagnosis, prevention, and treatment. Future rigorous clinical studies in humans will be necessary to validate these preliminary but promising results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sirtuins as regulators of metabolism and healthspan
Houtkooper, R. H., Pirinen, E., & Auwerx, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3293 · Cited by 2,008
Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease
Castera, L., Friedrich-Rust, M., & Loomba, R. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.036 · Cited by 1,494
Nakahata, Y., Kaluzova, M., Grimaldi, B., Sahar, S., Hirayama, J., Chen, D., Guarente, L. P., & Sassone-Corsi, P. (2008) · Cell · doi:10.1016/j.cell.2008.07.002 · Cited by 1,427 · cited 1×
“Additionally, SIRTs influence cells’ metabolism through the regulation of the circadian clock machinery with the deacetylation of central clock components in the liver [35,36].”
BackgroundSIRT1 regulates circadian clock gene expression through PER2 deacetylation
Asher, G., Gatfield, D., Stratmann, M., Reinke, H., Dibner, C., Kreppel, F., Mostoslavsky, R., Alt, F. W., & Schibler, U. (2008) · Cell · doi:10.1016/j.cell.2008.06.050 · Cited by 1,376
Yoshino, J., Mills, K. F., Yoon, M. J., & Imai, S.-I. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.08.014 · Cited by 1,340
NAD + repletion improves mitochondrial and stem cell function and enhances life span in mice
Zhang, H., Ryu, D., Wu, Y., Gariani, K., Wang, X., Luan, P., D’Amico, D., Ropelle, E. R., Lutolf, M. P., Aebersold, R., et al. (2016) · Science · doi:10.1126/science.aaf2693 · Cited by 1,255 · cited 2×
“studies demonstrated that the activity of SIRTs declines with aging by a systemic reduction in NAD levels [44,45].”
BackgroundCantó, C., Houtkooper, R. H., Pirinen, E., Youn, D. Y., Oosterveer, M. H., Cen, Y., Fernandez-Marcos, P. J., Yamamoto, H., Andreux, P. A., Cettour-Rose, P., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.022 · Cited by 1,238 · cited 8×
“These studies showed the powerful biological effects of NR in mitigating the negative consequences of HFDs [70,71,81,82], suggesting that NAD substrates supplementation may be a promising therapeutic strategy for preventing and treating NAFLD/NASH.”
BackgroundInfluentialNutrient-Sensitive Mitochondrial NAD+ Levels Dictate Cell Survival
Yang, H., Yang, T., Baur, J. A., Perez, E., Matsui, T., Carmona, J. J., Lamming, D. W., Souza-Pinto, N. C., Bohr, V. A., Rosenzweig, A., et al. (2007) · Cell · doi:10.1016/j.cell.2007.07.035 · Cited by 950 · cited 13×
“SIRTs’ activity is dependent on its cofactor NAD and it is sensitive to the cellular NAD levels [39], designating NAD as a rate-limiting substrate for their reactions [32,40,41].”
BackgroundInfluentialNampt/PBEF/Visfatin Regulates Insulin Secretion in β Cells as a Systemic NAD Biosynthetic Enzyme
Revollo, J. R., Körner, A., Mills, K. F., Satoh, A., Wang, T., Garten, A., Dasgupta, B., Sasaki, Y., Wolberger, C., Townsend, R. R., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.09.003 · Cited by 911 · cited 3×
“The extracellular NAMPT (eNAMPT) is secreted from adipocytes [18], hepatocytes [19], and leucocytes [20] and circulates in the blood where, additionally to its enzymatic function, it has also cytokine-like actions [16,21,22].”
BackgroundAcetyl-CoA and the regulation of metabolism: mechanisms and consequences
Shi, L., & Tu, B. P. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.02.003 · Cited by 903 · cited 1×
“The reduced coenzyme (NADH) is oxidized by leaving the protons and electrons to oxygen in the mitochondria to synthesize ATP in the electron transport system [48].”
BackgroundThe secret life of NAD+: an old metabolite controlling new metabolic signaling pathways
Houtkooper, R. H., Cantó, C., Wanders, R. J., & Auwerx, J. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0026 · Cited by 899 · cited 1×
“The relevance of dietary NAD precursors in health is well known, thanks to the historical use of NA and NAM in the treatment of dietary tryptophan deficits (pellagra) and hyperlipidemia, although high-dose NA use is limited by painful flushing, while high-dose NAM is hepatotoxic [74,75].”
BackgroundPARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation
Bai, P., Cantó, C., Oudart, H., Brunyánszki, A., Cen, Y., Thomas, C., Yamamoto, H., Huber, A., Kiss, B., Houtkooper, R. H., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.03.004 · Cited by 837 · cited 2×
“Another attractive angle to modulate NAD levels consists in targeting the activity of NAD-consuming enzymes, such as CD38 [10] and PARPs [11].”
BackgroundSirtuins deacetylate and activate mammalian acetyl-CoA synthetases
Hallows, W. C., Lee, S., & Denu, J. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604392103 · Cited by 792 · cited 2×
“The NAMPT is critical for the formation of acetyl-CoA and for the increase of fatty acid oxidation by providing NAD for SIRT3 with the activation of acetyl-CoA synthetase (ACS) [57].”
BackgroundSIRT1 transgenic mice show phenotypes resembling calorie restriction
Bordone, L., Cohen, D., Robinson, A., Motta, M. C., Van Veen, E., Czopik, A., Steele, A. D., Crowe, H., Marmor, S., Luo, J., et al. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2007.00335.x · Cited by 722 · cited 2×
“Conversely, caloric restriction increased NNMT liver expression, promoting SIRT1 protein stability, which mediates several metabolic effects of caloric restriction [60].”
BackgroundNicotinamide riboside is uniquely and orally bioavailable in mice and humans
Trammell, S. A. J., Schmidt, M. S., Weidemann, B. J., Redpath, P., Jaksch, F., Dellinger, R. W., Li, Z., Abel, E. D., Migaud, M. E., & Brenner, C. (2016) · Nature Communications · doi:10.1038/ncomms12948 · Cited by 697 · cited 1×
“[79] performed a clinical study enrolling 12 healthy subjects receiving three single doses of NR, demonstrating that NR supplementation safely induces NAD metabolism at all doses.”
BackgroundCalorie restriction extends yeast life span by lowering the level of NADH
Lin, S.-J., Ford, E., Haigis, M., Liszt, G., & Guarente, L. (2004) · Genes & Development · doi:10.1101/gad.1164804 · Cited by 632
A high-fat, ketogenic diet induces a unique metabolic state in mice
Kennedy, A. R., Pissios, P., Otu, H., Xue, B., Asakura, K., Furukawa, N., Marino, F. E., Liu, F.-F., Kahn, B. B., Libermann, T. A., et al. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00717.2006 · Cited by 420 · cited 2×
“The ketogenic diet suppresses liver NNMT expression, contributing to the increased liver and serum cholesterol levels in this model [59].”
BackgroundGomes, A. L., Teijeiro, A., Burén, S., Tummala, K. S., Yilmaz, M., Waisman, A., Theurillat, J.-P., Perna, C., & Djouder, N. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.020 · Cited by 401 · cited 1×
“Due to its ability to increase NAD synthesis without inducing side effects [44,70], NR has been used in mice to increase NAD metabolism and improve health in models of metabolic stress, showing that NR abolishes DNA damage in HFD-fed mice [70,78].”
BackgroundFatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation
Kendrick, A. A., Choudhury, M., Rahman, S. M., McCurdy, C. E., Friederich, M., Van Hove, J. L. K., Watson, P. A., Birdsey, N., Bao, J., Gius, D., et al. (2011) · Biochemical Journal · doi:10.1042/bj20100791 · Cited by 382 · cited 1×
“SIRTs’ activity is dependent on its cofactor NAD and it is sensitive to the cellular NAD levels [39], designating NAD as a rate-limiting substrate for their reactions [32,40,41].”
BackgroundGariani, K., Menzies, K. J., Ryu, D., Wegner, C. J., Wang, X., Ropelle, E. R., Moullan, N., Zhang, H., Perino, A., Lemos, V., et al. (2016) · Hepatology · doi:10.1002/hep.28245 · Cited by 368
Flavonoid Apigenin Is an Inhibitor of the NAD+ase CD38
Escande, C., Nin, V., Price, N. L., Capellini, V., Gomes, A. P., Barbosa, M. T., O’Neil, L., White, T. A., Sinclair, D. A., & Chini, E. N. (2013) · Diabetes · doi:10.2337/db12-1139 · Cited by 332 · cited 1×
“The treatment of obese mice with CD38 inhibitors augments intracellular NAD concentrations and improves glucose and lipid homeostasis [86].”
BackgroundNicotinamide Riboside Opposes Type 2 Diabetes and Neuropathy in Mice
Trammell, S. A. J., Weidemann, B. J., Chadda, A., Yorek, M. S., Holmes, A., Coppey, L. J., Obrosov, A., Kardon, R. H., Yorek, M. A., & Brenner, C. (2016) · Scientific Reports · doi:10.1038/srep26933 · Cited by 301 · cited 1×
“These studies showed the powerful biological effects of NR in mitigating the negative consequences of HFDs [70,71,81,82], suggesting that NAD substrates supplementation may be a promising therapeutic strategy for preventing and treating NAFLD/NASH.”
BackgroundWang, X., Hu, X., Yang, Y., Takata, T., & Sakurai, T. (2016) · Brain Research · doi:10.1016/j.brainres.2016.04.060 · Cited by 217 · cited 1×
“Supplementation with NMN, an enzymatic product of NAMPT, improves diabetes [12,13] and other damages such as vascular dysfunction, oxidative stress [83], and cognitive impairment [84].”
BackgroundNAD + metabolism: A therapeutic target for age-related metabolic disease
Mouchiroud, L., Houtkooper, R. H., & Auwerx, J. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.789479 · Cited by 193 · cited 4×
“The precursors NA, NMN, and NR, but also PARP or CD38 inhibitors, rise NAD levels in different mice cells and tissues [12,13,70].”
BackgroundInfluentialShi, W., Hegeman, M. A., van Dartel, D. A. M., Tang, J., Suarez, M., Swarts, H., van der Hee, B., Arola, L., & Keijer, J. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201600878 · Cited by 62
PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS
Almeida, G. S., Bawn, C. M., Galler, M., Wilson, I., Thomas, H. D., Kyle, S., Curtin, N. J., Newell, D. R., & Maxwell, R. J. (2017) · NMR in Biomedicine · doi:10.1002/nbm.3736 · Cited by 16 · cited 1×
“Rucaparib (a PARP inhibitor) significantly increases hepatic NAD levels, as previously described with NAM treatment [88], while in PARP1 KO liver, NAD levels were similar to those in treated PARP1 WT liver.”
Background
Cited by
NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential
Xie, N., Zhang, L., Gao, W., Huang, C., Huber, P. E., Zhou, X., Li, C., Shen, G., & Zou, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00311-7 · Cited by 1,052
Brakedal, B., Dölle, C., Riemer, F., Ma, Y., Nido, G. S., Skeie, G. O., Craven, A. R., Schwarzlmüller, T., Brekke, N., Diab, J., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.001 · Cited by 323
Cellular Mechanisms of Liver Fibrosis
Acharya, P., Chouhan, K., Weiskirchen, S., & Weiskirchen, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.671640 · Cited by 252
En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH
Kimura, M., Iguchi, T., Iwasawa, K., Dunn, A., Thompson, W. L., Yoneyama, Y., Chaturvedi, P., Zorn, A. M., Wintzinger, M., Quattrocelli, M., et al. (2022) · Cell · doi:10.1016/j.cell.2022.09.031 · Cited by 115
Paolini, E., Longo, M., Meroni, M., Tria, G., Cespiati, A., Lombardi, R., Badiali, S., Maggioni, M., Fracanzani, A. L., & Dongiovanni, P. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1101341 · Cited by 11
Metadata
- Authors
- Guarino, M., & Dufour, J.-F.
- Venue
- Metabolites
- Publisher
- MDPI AG
- Published
- 2019-09-10
- Volume
- 9
- Issue
- 9
- Pages
- 180
- ISSN
- 2218-1989 (ISSN-L)
- OpenAlex
- W2972323634
- Cited by
- 25
- References
- 26
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.